Amedisys (NASDAQ:AMED) Lowered to “Market Perform” at William Blair

William Blair downgraded shares of Amedisys (NASDAQ:AMED) from an outperform rating to a market perform rating in a report issued on Monday morning, Marketbeat.com reports.

A number of other research analysts have also issued reports on the stock. Raymond James reiterated a market perform rating on shares of Amedisys in a research note on Tuesday, March 26th. Royal Bank of Canada boosted their target price on Amedisys from $97.00 to $100.00 and gave the stock an outperform rating in a research report on Monday, March 25th. Cantor Fitzgerald reissued a neutral rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday, April 25th. Finally, StockNews.com upgraded Amedisys from a hold rating to a buy rating in a research note on Saturday, May 4th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus target price of $100.67.

Amedisys Stock Up 0.6 %

AMED opened at $97.30 on Monday. The business has a 50 day moving average price of $93.55 and a two-hundred day moving average price of $93.51. Amedisys has a 52 week low of $89.55 and a 52 week high of $97.50. The company has a market cap of $3.18 billion, a PE ratio of -152.03, a P/E/G ratio of 2.37 and a beta of 0.79. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The business had revenue of $571.41 million during the quarter, compared to analysts’ expectations of $565.38 million. During the same quarter in the prior year, the business earned $1.00 earnings per share. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, research analysts anticipate that Amedisys will post 4.57 EPS for the current year.

Institutional Investors Weigh In On Amedisys

Institutional investors have recently modified their holdings of the company. Qube Research & Technologies Ltd acquired a new position in Amedisys during the third quarter worth $1,983,000. Toronto Dominion Bank purchased a new stake in shares of Amedisys in the 3rd quarter worth about $4,810,000. Carmignac Gestion boosted its position in shares of Amedisys by 373.2% in the 3rd quarter. Carmignac Gestion now owns 33,725 shares of the health services provider’s stock worth $3,150,000 after buying an additional 26,598 shares in the last quarter. Hudson Bay Capital Management LP grew its stake in Amedisys by 926.5% in the 3rd quarter. Hudson Bay Capital Management LP now owns 166,456 shares of the health services provider’s stock valued at $15,547,000 after acquiring an additional 150,240 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in Amedisys by 96.9% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 10,922 shares of the health services provider’s stock valued at $1,020,000 after acquiring an additional 5,375 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.